

PATIENTS HAVE AN ALTERNATIVE TO EXPENSIVE BIOLOGIC MEDICINES

Biologics are innovative treatment options for a wide range of patients with:

- Rheumatoid arthritis
- Cancer
- Crohn's disease
- Other chronic or life-threatening diseases



WHAT ARE BIOLOGICS?

Biologic medicines (or reference products) are large-molecule products that involve complex research, development and manufacturing processes. They are often expensive, limiting access for many patients.

WHAT ARE BIOSIMILARS?

Biosimilars are FDA-approved alternatives to reference biologics – **much like generic drugs** – that provide treatment options for patients who need biologic medicines to manage their conditions.

ROUGHLY 2%
Of U.S. patients use biologics

Source: www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf

OVER 50%
Of prescription drug spending in the U.S. is for biologics

Source: www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf

BIOSIMILARS MEANS BIG SAVINGS AND MORE ACCESS

\$54 billion

Potential savings to health care system over next 10 years

Source: www.rand.org/pubs/periodicals/health_quarterly/issues/v7/n4/03.html

OVER 1,200,000

More patients in U.S. could receive needed treatments

Source: www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf

Wider access to biosimilars benefits everybody: patients, doctors and payers. **Let's increase access to biosimilar medicines.**



WHAT DOCTORS NEED TO KNOW



BE INFORMED

Make sure you can educate your patients and combat misinformation:

A biosimilar is a biologic that is highly similar to, and has no clinically meaningful differences from, another biologic that's already approved by the [FDA](https://www.fda.gov).



THE NAME GAME

Learn about biosimilar naming conventions and the four-letter suffix that identifies them from their reference product from the [FDA's Purple Book](#).



UNDERSTAND WHAT'S AVAILABLE

Since different payers are likely to prefer different products, it will be important to know what biosimilars are available for specific reference products in order to be reimbursed properly.



WHAT PAYERS NEED TO KNOW



Biosimilars are on average 30% cheaper than their reference product.

Source: CMS HCPCS Coding Files, July 2020



Include biosimilars on a formulary tier that makes them a viable choice for patients.



Drive down health costs by providing competitive options, giving patients access to important medicines.



WHAT PATIENTS NEED TO KNOW



Ask your doctor about biosimilars if you are currently on an expensive biologic medication and take control of your health care spending.



The FDA is a valuable resource for biosimilars information. [Learn more.](#)



Listen to health care professionals who are experts in biosimilars and beware misinformation.

Biosimilars benefit us all

Wider access to biosimilars benefits patients, doctors and payers. **Let's increase access to biosimilars.**

Learn more about biosimilars biosimilarscouncil.org/advocacy

Biosimilars Council
A Division of the Association for Accessible Medicines

aam
Association for Accessible Medicines